Alpha-1 Foundation Series
Cholestatic and Advanced Liver Disease, Risk Factors, Testing and Treatments in Pediatric Patients with Alpha-1 Antitrypsin Deficiency
Release date: October 25, 2022
Expiration date: October 25, 2025
Estimated Time of Completion: 30 minutes
Description
Participate in the on-demand webcast series designed for healthcare professions to improve knowledge and competence in diagnostics and treatment of Alpha-1 Antitrypsin Deficiency (AATD). The Cholestatic and Advanced Liver Disease, Risk Factors, Testing and Treatments in Pediatric Patients with Alpha-1 Antitrypsin Deficiency webcast provides a patient testimonial and addresses the following questions:
- When should a person be tested for Alpha-1 based on liver findings?
- What are the risk factors for liver disease in Alpha-1?
- How should the child with AATD be followed and treated?
Disclosures
In accordance with the Standards for Integrity and Independence issued by the Accreditation Council for Continuing Medical Education (ACCME), Cleveland Clinic Center for Continuing Education mitigates all relevant conflicts of interest to ensure CME activities are free of commercial bias.
The following faculty member has indicated that he may have a relationship, which in the context of his presentation(s), could be perceived as a potential conflict of interest:
James Stoller, MD, MS | |
CSL Behring | Consulting Teaching and Speaking |
Takeda | Consulting Other activities from which remuneration is received or expected: participation on a data monitoring committee for a trial regarding alpha-1 antitrypsin deficiency |
Vertex Pharmaceuticals | Consulting Other activities from which remuneration is received or expected: consulting regarding alpha-1 antitrypsin deficiency |
Grifols | Consulting Teaching and Speaking |
Arrowhead | Consulting |
Insmed, Inc. | Consulting Other activities from which remuneration is received or expected: regarding alpha-1 antitrypsin deficiency |
23andMe | Consulting Other activities from which remuneration is received or expected: participating in research on detection of alpha-1 antitrypsin deficiency prepared teaching materials re alpha-1 antitrypsin deficiency Teaching and Speaking |
InhibRx | Consulting Other activities from which remuneration is received or expected: regarding alpha-1 antitrypsin deficiency |
Dicerna Pharmaceuticals | Consulting |
korro | Consulting |
4dmt | Consulting |
Charlie Strange, MD | |
Adverum Biotechnologies, Inc. | Principal or Co-Investigator of funded research |
Astra Zeneca | Consulting |
CSL Behring | Advisor or review panel participant |
Grifols | Principal or Co-Investigator of funded research |
Takeda | Principal or Co-Investigator of funded research |
Vertex Pharmaceuticals | Principal or Co-Investigator of funded research |
Jeff Teckman, MD | |
Arrowhead Research Corporation | Consulting Research: Site PI |
BioMarin | Consulting |
Centessa | Consulting Research: study design |
Dicerna Pharmaceuticals | Consulting |
Intellia | Consulting |
KorroBio | Consulting Research: preclinical studies |
Takeda Pharmaceutical Ltd | Consulting |
Vertex Pharmaceuticals | Consulting Research: site PI |
All Cleveland Clinic Center for Continuing Education and Alpha-1 Foundation planners and patients have indicated that they have no relationship which in the context of their participation could be considered a conflict of interest.
This CME activity was produced by The Cleveland Clinic Center for Continuing Education and the Alpha-1 Foundation.